Aurinia Pharmaceuticals (AUPH) Competitors

ADMA Biologics (NASDAQ:ADMA) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Does the media prefer ADMA or AUPH?

In the previous week, ADMA Biologics had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 8 mentions for ADMA Biologics and 5 mentions for Aurinia Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.40 beat Aurinia Pharmaceuticals' score of 0.36 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger valuation & earnings, ADMA or AUPH?

ADMA Biologics has higher revenue and earnings than Aurinia Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	10.24	$197.67M	$0.85	21.52
Aurinia Pharmaceuticals	$235.13M	4.35	$5.75M	$0.28	27.02

Do institutionals & insiders believe in ADMA or AUPH?

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts rate ADMA or AUPH?

ADMA Biologics presently has a consensus target price of $27.67, indicating a potential upside of 51.23%. Aurinia Pharmaceuticals has a consensus target price of $11.50, indicating a potential upside of 52.00%. Given Aurinia Pharmaceuticals' higher possible upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ADMA or AUPH more profitable?

ADMA Biologics has a net margin of 45.01% compared to Aurinia Pharmaceuticals' net margin of 16.11%. ADMA Biologics' return on equity of 47.16% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	45.01%	47.16%	30.51%
Aurinia Pharmaceuticals	16.11%	14.27%	9.93%

Which has more volatility & risk, ADMA or AUPH?

ADMA Biologics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.

Summary

ADMA Biologics beats Aurinia Pharmaceuticals on 12 of the 16 factors compared between the two stocks.